In this preclinical study, we set out to investigate the impact of tovorafenib alone or in combination with MEK inhibitor pimasertib in adult or pediatric tumor models harboring either an AGK::BRAF fusion or an NF1-LOF mutation. Here, MAP2K7 is linked to neoplasm.